Associate Professor and Clinical Pharmacist Touro University California Fairfield, California, United States
This poster provides an update on dyslipidemia management recommendations relating to diabetes and cardiovascular risk reduction. In addition, a summary of novel antilipidemic agents (e.g., inclisiran, alirocumab, evolocumab, bempedoic acid, and icosapent ethyl) and their associated CVOTs are included, as some of these agents have been approved for established ASCVD. The poster author includes information on the existing agents, e.g., statins, fibrates, niacin, omega-3 fatty acids, ezetimibe, PCSK-9 inhibitors, and bile acid-binding resins and a patient case to assist in applying guideline recommendations and implementing a treatment and monitoring plan.
